Metaphorebio
2 known investors
Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.
AI & Machine LearningBiotechDeep TechMedical Devices
Investors Β· 2
Competitors Β· 2
by search overlapFore20 shared keywordsFore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program. It runs clinical trials such as the Forte Trial and offers expanded access programs for patients.
Bioworld18 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Metaphorebio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Metaphorebio do?
- Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.
- Who are Metaphorebio's investors?
- Metaphorebio's investors include Flagship Pioneering, Global Brain.